Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: A multicentre, open-label, phase 2 trial

The Lancet Oncology

Volumn 14, Issue 4, 2013, Pages 371-382

  Schwartz, Gary K ^a   Tap, William D ^a   Qin, Li Xuan ^a   Livingston, Michael B ^b   Undevia, Samir D ^c   Chmielowski, Bartosz ^d   Agulnik, Mark ^e   Schuetze, Scott M ^f   Reed, Damon R ^g   Okuno, Scott H ^h   Ludwig, Joseph A ⁱ   Keedy, Vicki ^j   Rietschel, Petra ^k   Kraft, Andrew S ^l   Adkins, Douglas ^m   Van Tine, Brian A ^m   Brockstein, Bruce ^e   Yim, Vincent ^a   Bitas, Christiana ^a   Abdullah, Abdul ^a   Antonescu, Cristina R ^a   Condy, Mercedes ^a   Dickson, Mark A ^a   Vasudeva, Shyamprasad Deraje ^a   Ho, Alan L ^a   Doyle, L Austin ⁿ   Chen, Helen X ⁿ   Maki, Robert G ^o   more..

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b LEVINE CANCER INSTITUTE   (United States)

^c UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e NORTHWESTERN UNIVERSITY   (United States)

^f UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^g H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^h MAYO CLINIC   (United States)

ⁱ UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^j VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^k ALBERT EINSTEIN CANCER CENTER   (United States)

^l MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^m WASHINGTON UNIVERSITY   (United States)

ⁿ NATIONAL CANCER INSTITUTE   (United States)

^o MOUNT SINAI SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CIXUTUMUMAB; SOMATOMEDIN C RECEPTOR; TEMSIROLIMUS;

ABDOMINAL PAIN; ACNE; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ALLERGIC RHINITIS; ALOPECIA; ANEMIA; ANXIETY DISORDER; ARTHRALGIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACKACHE; CANCER MORTALITY; CHOLESTEROL BLOOD LEVEL; CHONDROSARCOMA; CONNECTIVE TISSUE DISEASE; CONSTIPATION; COUGHING; CREATININE BLOOD LEVEL; DEHYDRATION; DEPRESSION; DIARRHEA; DIZZINESS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRY SKIN; DYSGEUSIA; DYSPNEA; EPISTAXIS; EWING SARCOMA; FATIGUE; FEMALE; FEVER; FLU LIKE SYNDROME; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL STROMAL TUMOR; HEADACHE; HUMAN; HYPERCALCEMIA; HYPERGLYCEMIA; HYPERKALEMIA; HYPERTRIGLYCERIDEMIA; HYPOALBUMINEMIA; HYPOCALCEMIA; HYPOGLYCEMIA; HYPOKALEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; HYPOTENSION; HYPOXIA; IMMUNOHISTOCHEMISTRY; INSOMNIA; INTENTION TO TREAT ANALYSIS; INTERNATIONAL NORMALIZED RATIO; LEIOMYOSARCOMA; LEUKOPENIA; LIPOSARCOMA; LYMPHOCYTOPENIA; MACULOPAPULAR RASH; MAJOR CLINICAL STUDY; MALE; MALIGNANT PERIPHERAL NERVE SHEATH TUMOR; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MUSCLE WEAKNESS; MUSCULOSKELETAL DISEASE; MYALGIA; NAIL DISEASE; NAIL INFECTION; NAIL RIDGING; NAUSEA; NEUROECTODERM TUMOR; NEUTROPENIA; NOSE OBSTRUCTION; OPEN STUDY; ORAL MUCOSITIS; OSTEOSARCOMA; OVERALL SURVIVAL; PAIN; PARESTHESIA; PARONYCHIA; PARTIAL THROMBOPLASTIN TIME; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PREDICTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PRURITUS; SENSORY NEUROPATHY; SIDE EFFECT; SINUSITIS; SKIN BRUISING; SKIN INFECTION; SOFT TISSUE SARCOMA; SOLITARY FIBROUS TUMOR; SORE THROAT; SYNOVIAL SARCOMA; THORAX PAIN; THROMBOCYTOPENIA; TREATMENT OUTCOME; UNITED STATES; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VOMITING; WEIGHT REDUCTION; XEROSTOMIA;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; DISEASE-FREE SURVIVAL; DRUG TOXICITY; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; PROTEIN KINASE INHIBITORS; RECEPTOR, IGF TYPE 1; SARCOMA; SIROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 84875803717     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(13)70049-4     Document Type: Article

References (21)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ Cancer statistics, 2007. CA Cancer J Clin 2007, 57:43-66.
2. Brennan M, Singer S, Maki R, O'Sullivan B Soft tissue sarcoma. Cancer: principles & practices of oncology 2008, volume 2:1741-1794. Lippincott, Williams & Wilkins, Philadelphia. 8th edn. V.T. DeVita, T.S. Lawrence, S.A. Rosenberg (Eds.).
3. Baird K, Davis S, Antonescu CR, et al. Gene expression profiling of human sarcomas: insights into sarcoma biology. Cancer Res 2005, 65:9226-9235.
4. Olmos D, Tan DS, Jones RL, Judson IR Biological rationale and current clinical experience with anti-insulin-like growth factor 1 receptor monoclonal antibodies in treating sarcoma: twenty years from the bench to the bedside. Cancer J 2010, 16:183-194.
5. Prieur A, Tirode F, Cohen P, Delattre O EWS/FLI-1 silencing and gene profiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3. Mol Cell Biol 2004, 24:7275-7283.
6. Scotlandi K, Manara MC, Nicoletti G, et al. Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors. Cancer Res 2005, 65:3868-3876.
7. Sekyi-Otu A, Bell RS, Ohashi C, Pollak M, Andrulis IL Insulin-like growth factor 1 (IGF-1) receptors, IGF-1, and IGF-2 are expressed in primary human sarcomas. Cancer Res 1995, 55:129-134.
8. Toretsky JA, Kalebic T, Blakesley V, LeRoith D, Helman LJ The insulin-like growth factor-I receptor is required for EWS/FLI-1 transformation of fibroblasts. J Biol Chem 1997, 272:30822-30827.
9. Juergens H, Daw NC, Geoerger B, et al. Preliminary efficacy of the anti-insulin-like growth factor type 1 receptor antibody figitumumab in patients with refractory Ewing sarcoma. J Clin Oncol 2011, 29:4534-4540.
10. Pappo AS, Patel SR, Crowley J, et al. R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II Sarcoma Alliance for Research through Collaboration study. J Clin Oncol 2011, 29:4541-4547.
11. Kolb EA, Gorlick R, Maris JM, et al. Combination testing (stage 2) of the anti-IGF-1 receptor antibody IMC-A12 with rapamycin by the pediatric preclinical testing program. Pediatr Blood Cancer 2012, 58:729-735.
12. Wan X, Harkavy B, Shen N, Grohar P, Helman LJ Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene 2007, 26:1932-1940.
13. O'Reilly KE, Rojo F, She QB, et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006, 66:1500-1508.
14. Okuno S, Bailey H, Mahoney MR, et al. A phase 2 study of temsirolimus (CCI-779) in patients with soft tissue sarcomas: a study of the Mayo phase 2 consortium (P2C). Cancer 2011, 117:3468-3475.
15. Ho AL, Vasudeva SD, Lae M, et al. PDGF receptor alpha is an alternative mediator of rapamycin-induced Akt activation: implications for combination targeted therapy of synovial sarcoma. Cancer Res 2012, 72:4515-4525.
16. Naing A, LoRusso P, Fu S, et al. Insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing's sarcoma family tumors. Clin Cancer Res 2012, 18:2625-2631.
17. Quek R, Wang Q, Morgan JA, et al. Combination mTOR and IGF-1R inhibition: phase I trial of everolimus and figitumumab in patients with advanced sarcomas and other solid tumors. Clin Cancer Res 2011, 17:871-879.
18. Lasota J, Wang Z, Kim SY, Helman L, Miettinen M Expression of the receptor for type I insulin-like growth factor (IGF1R) in gastrointestinal stromal tumors: an immunohistochemical study of 1078 cases with diagnostic and therapeutic implications. Am J Surg Pathol 2013, 37:114-119.
19. Van Blabbeke M, Verweij J, Judson I, Nielsen OS Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas. Eur J Cancer 2002, 38:543-549.
20. Simon R Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989, 10:1-10.
21. Sleijfer S, Ray-coquard I, Papi Z, et al. Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043). J Clin Oncol 2009, 27:3126-3132.